A new drug for Alzheimer’s disease called Rember is being praised by the National Institute on Aging. This drug is only in the earliest stages of testing, but is showing amazing results. The National Institute on Aging — one of the National Institutes of Health here in the United States — helped fund early research that led to the development of drugs like Rember. These drugs are designed to target tau proteins in the tangles that form in the brain of a person with Alzheimer’s disease. For decades, medical research on Alzheimer’s disease has focused on a different kind of … Continue reading →